FB   240.28 (+2.94%)
GOOGL   1,499.65 (+2.02%)
AMZN   3,057.04 (+5.77%)
NVDA   393.57 (+2.36%)
CGC   16.94 (+2.98%)
BABA   240.00 (+7.33%)
MU   50.92 (+2.19%)
GE   7.00 (+2.64%)
TSLA   1,371.58 (+13.48%)
AMD   53.40 (+2.03%)
ACB   12.18 (-0.73%)
F   6.19 (+2.31%)
DIS   114.43 (+2.01%)
BAC   23.66 (+1.59%)
NFLX   493.81 (+3.55%)
BA   187.91 (+3.93%)
FB   240.28 (+2.94%)
GOOGL   1,499.65 (+2.02%)
AMZN   3,057.04 (+5.77%)
NVDA   393.57 (+2.36%)
CGC   16.94 (+2.98%)
BABA   240.00 (+7.33%)
MU   50.92 (+2.19%)
GE   7.00 (+2.64%)
TSLA   1,371.58 (+13.48%)
AMD   53.40 (+2.03%)
ACB   12.18 (-0.73%)
F   6.19 (+2.31%)
DIS   114.43 (+2.01%)
BAC   23.66 (+1.59%)
NFLX   493.81 (+3.55%)
BA   187.91 (+3.93%)
FB   240.28 (+2.94%)
GOOGL   1,499.65 (+2.02%)
AMZN   3,057.04 (+5.77%)
NVDA   393.57 (+2.36%)
CGC   16.94 (+2.98%)
BABA   240.00 (+7.33%)
MU   50.92 (+2.19%)
GE   7.00 (+2.64%)
TSLA   1,371.58 (+13.48%)
AMD   53.40 (+2.03%)
ACB   12.18 (-0.73%)
F   6.19 (+2.31%)
DIS   114.43 (+2.01%)
BAC   23.66 (+1.59%)
NFLX   493.81 (+3.55%)
BA   187.91 (+3.93%)
FB   240.28 (+2.94%)
GOOGL   1,499.65 (+2.02%)
AMZN   3,057.04 (+5.77%)
NVDA   393.57 (+2.36%)
CGC   16.94 (+2.98%)
BABA   240.00 (+7.33%)
MU   50.92 (+2.19%)
GE   7.00 (+2.64%)
TSLA   1,371.58 (+13.48%)
AMD   53.40 (+2.03%)
ACB   12.18 (-0.73%)
F   6.19 (+2.31%)
DIS   114.43 (+2.01%)
BAC   23.66 (+1.59%)
NFLX   493.81 (+3.55%)
BA   187.91 (+3.93%)
Log in

NASDAQ:BDSIBioDelivery Sciences International Stock Price, Forecast & News

$4.49
+0.04 (+0.90 %)
(As of 07/6/2020 04:00 PM ET)
Add
Compare
Today's Range
$4.42
Now: $4.49
$4.58
50-Day Range
$4.11
MA: $4.62
$5.19
52-Week Range
$2.85
Now: $4.49
$7.21
Volume1.12 million shs
Average Volume993,843 shs
Market Capitalization$449.26 million
P/E RatioN/A
Dividend YieldN/A
Beta0.75
BioDelivery Sciences International, Inc., a specialty pharmaceutical company, engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company provides its products based on its patented BioErodible MucoAdhesive drug-delivery technology, a small erodible polymer film for application to the buccal mucosa, as well as other drug-delivery technologies. It offers BELBUCA, a buprenorphine buccal film for the treatment of chronic pain; BUNAVAIL, a buprenorphine and naloxone buccal film to treat opioid dependence; and ONSOLIS, a fentanyl buccal soluble film for the management of breakthrough pain in opioid tolerant adult patients with cancer. The company also develops buprenorphine extended release injection, an injectable microparticle formulation of buprenorphine for the treatment of opioid dependence and chronic pain. BioDelivery Sciences International, Inc. was founded in 1997 and is headquartered in Raleigh, North Carolina.
Read More
BioDelivery Sciences International logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.4Community Rank: 3.1Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 1.9 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.88 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
Current SymbolNASDAQ:BDSI
CUSIP09060J10
Phone919-582-9050

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$111.39 million
Cash Flow$0.19 per share
Book Value$0.78 per share

Profitability

Net Income$-15,310,000.00

Miscellaneous

Employees178
Market Cap$449.26 million
Next Earnings Date8/13/2020 (Estimated)
OptionableOptionable

Receive BDSI News and Ratings via Email

Sign-up to receive the latest news and ratings for BDSI and its competitors with MarketBeat's FREE daily newsletter.

BioDelivery Sciences International (NASDAQ:BDSI) Frequently Asked Questions

How has BioDelivery Sciences International's stock been impacted by COVID-19 (Coronavirus)?

BioDelivery Sciences International's stock was trading at $3.96 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, BDSI shares have increased by 13.3% and is now trading at $4.4850. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of BioDelivery Sciences International?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BioDelivery Sciences International in the last year. There are currently 1 hold rating and 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for BioDelivery Sciences International.

When is BioDelivery Sciences International's next earnings date?

BioDelivery Sciences International is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for BioDelivery Sciences International.

How were BioDelivery Sciences International's earnings last quarter?

BioDelivery Sciences International, Inc. (NASDAQ:BDSI) released its earnings results on Thursday, May, 7th. The specialty pharmaceutical company reported $0.05 earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of $0.01 by $0.04. The specialty pharmaceutical company earned $38.28 million during the quarter, compared to analysts' expectations of $33.19 million. BioDelivery Sciences International had a negative net margin of 5.01% and a positive return on equity of 23.61%. View BioDelivery Sciences International's earnings history.

What price target have analysts set for BDSI?

8 Wall Street analysts have issued 1 year price targets for BioDelivery Sciences International's stock. Their forecasts range from $8.00 to $9.25. On average, they anticipate BioDelivery Sciences International's share price to reach $8.71 in the next year. This suggests a possible upside of 94.2% from the stock's current price. View analysts' price targets for BioDelivery Sciences International.

Has BioDelivery Sciences International been receiving favorable news coverage?

News articles about BDSI stock have been trending negative this week, InfoTrie Sentiment reports. InfoTrie ranks the sentiment of media coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. BioDelivery Sciences International earned a media sentiment score of -2.1 on InfoTrie's scale. They also assigned headlines about the specialty pharmaceutical company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the company's share price in the next several days. View the latest news about BioDelivery Sciences International.

Who are some of BioDelivery Sciences International's key competitors?

What other stocks do shareholders of BioDelivery Sciences International own?

Based on aggregate information from My MarketBeat watchlists, some companies that other BioDelivery Sciences International investors own include TG Therapeutics (TGTX), Eldorado Gold (EGO), NVIDIA (NVDA), Inovio Pharmaceuticals (INO), Synergy Pharmaceuticals (SGYP), Alibaba Group (BABA), Baidu (BIDU), JD.Com (JD), Crispr Therapeutics (CRSP) and Gilead Sciences (GILD).

Who are BioDelivery Sciences International's key executives?

BioDelivery Sciences International's management team includes the following people:
  • Mr. Herm Cukier, CEO & Director (Age 54, Pay $599.46k)
  • Mr. Scott M. Plesha, Pres & Chief Commercial Officer (Age 55, Pay $410.71k)
  • Ms. Mary Theresa Coelho, CFO & Treasurer (Age 58, Pay $410.7k)
  • Mr. James Vollins J.D., Gen. Counsel, Chief Compliance Officer & Corp. Sec. (Age 51, Pay $340.28k)
  • Dr. Thomas B. Smith FAAFP, M.D., Chief Medical Officer (Age 59, Pay $377.89k)

What is BioDelivery Sciences International's stock symbol?

BioDelivery Sciences International trades on the NASDAQ under the ticker symbol "BDSI."

How do I buy shares of BioDelivery Sciences International?

Shares of BDSI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is BioDelivery Sciences International's stock price today?

One share of BDSI stock can currently be purchased for approximately $4.49.

How big of a company is BioDelivery Sciences International?

BioDelivery Sciences International has a market capitalization of $449.26 million and generates $111.39 million in revenue each year. The specialty pharmaceutical company earns $-15,310,000.00 in net income (profit) each year or $0.10 on an earnings per share basis. BioDelivery Sciences International employs 178 workers across the globe.

What is BioDelivery Sciences International's official website?

The official website for BioDelivery Sciences International is www.bdsi.com.

How can I contact BioDelivery Sciences International?

BioDelivery Sciences International's mailing address is 4131 PARKLAKE AVENUE SUITE 225, RALEIGH NC, 27612. The specialty pharmaceutical company can be reached via phone at 919-582-9050 or via email at [email protected]

This page was last updated on 7/6/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.